Physician profile
Clinton C Haley
NPI 1871733188
$17,129.69
in general payments reported to CMS, 2019-2025
30 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $906 · 2021: $1,482 · 2022: $2,623 · 2023: $2,906 · 2024: $3,693 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,741 · Education: $55.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,741.02 |
| Education | $55.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,811.74 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $1,306.79 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $1,212.71 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $1,157.59 | 2019-2025 | Biktarvy |
| Paratek Pharmaceuticals, INC. | $806.38 | 2020-2025 | Nuzyra |
| Abbvie INC. | $731.33 | 2021-2025 | |
| Emd Serono, INC. | $681.76 | 2019-2024 | Serostim |
| Janssen Biotech, INC. | $653.17 | 2019-2023 | Symtuza |
| Shionogi INC | $588.86 | 2021-2025 | Fetroja |
| Astellas Pharma US INC | $569.13 | 2019-2025 | Cresemba |
| Theratechnologies INC. | $510.97 | 2019-2025 | Trogarzo, Egrifta |
| Ferring Pharmaceuticals INC. | $418.12 | 2022-2025 | Rebyota, Clenpiq |
| Aimmune Therapeutics, INC. | $347.99 | 2023-2025 | Vowst, Zenpep |
| Napo Pharmaceuticals INC | $333.94 | 2019-2024 | Mytesi |
| Takeda Pharmaceuticals U.S.A., INC. | $283.98 | 2021-2025 | Livtencity, Hyqvia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $261.23 | 2019-2025 | Vibativ |
| Mayne Pharma Commercial LLC | $205.34 | 2019-2021 | |
| Grifols USA, LLC | $200.91 | 2019-2025 | Gamunex-C |
| Melinta Therapeutics, LLC | $188.50 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| La Jolla Pharmaceutical Company | $169.50 | 2021-2024 | Xerava |
| Amgen INC. | $108.57 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $105.71 | 2019-2020 | |
| Pfizer INC. | $97.98 | 2019-2025 | |
| Allergan, INC. | $87.16 | 2019 | |
| Hospira, INC. | $69.47 | 2024-2025 | |
| Invivyd INC | $59.35 | 2024-2025 | Pemgarda |
| Nabriva Therapeutics, Plc | $52.58 | 2020-2021 | |
| Octapharma USA, INC. | $51.61 | 2024-2025 | Octagam Immune Globulin (Human) |
| Amarin Pharma, INC. | $46.24 | 2021 | |
| Dynavax Technologies Corporation | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Haley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.